VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Table 1 Patient characteristics

Characteristic	All (stained)		FLO		FLP		VEGFR-3 +		VEGFR-3 -		CXCR4 +		CXCR4 -
	n		n		n		n		n		n		n
Number	72		38		34		39		30		26		44
Age (years)		SD +/−		SD +/−		SD +/−		SD +/−		SD +/−		SD +/−		SD +/−
Mean	59.8	12.04	59.7	12.76	59.9	11.39	62.4	12.33	55.6	10.8	59	12.6	60	11.95
Range	33.1-84.2		33.1-84.2		34.7-78.9		34.7-84.2		33.1-78.9		33.1-84.2		34.7-78.9
Gender		%		%		%		%		%		%		%
Male	48	66.7	19	50	29	85.3	26	66.7	19	63.3	19	73.1	28	63.6
Female	24	33.3	19	50	5	14.7	13	33.3	11	36.7	7	26.9	16	36.4
Primary
Cardia	19	26.4	10	26.3	9	27.3	10	25.6	7	24.1	6	23.1	12	27.9
Corpus	27	37.5	15	39.5	12	36.4	14	35.9	12	41.4	12	46.2	15	34.9
Antrum	13	18.1	7	18.4	6	18.2	7	17.9	6	20.7	4	15.4	9	20.9
Esophagus	2	2.8	1	2.6	1	3	2	5.1	0	0	0	0	1	2.3
Stomach	6	8.3	2	5.3	4	12.1	4	10.3	2	6.9	2	7.7	4	9.3
No information	4	5.6	3	7.9	1	3	2	5.1	2	6.9	2	7.7	2	4.7

ISSN: 1471-2407